Therapeutic effect and mechanism of quetiapine in a transgenic mouse model of Alzheimer’s disease.

− この都医学研セミナーは終了しました。 −

演者 何(カ)珏(カク)
(Jue He)
Mental Health Research Unit, Xiamen Xian Yue Hospital (Professor)
会場 東京都医学総合研究所 2階 講堂
日時 平成29年6月7日(水)10:00~
世話人 前田 信明 (脳発達・神経再生研究分野 神経回路形成プロジェクトリーダー)
参加自由 詳細は下記問合せ先まで
お問い合わせ 研究推進課 普及広報係
電話 03-5316-3109


In the present study, we investigated the therapeutic effects of quetiapine, an atypical antipsychotic drug, on memory impairment and its possible beneficial effects on brain pathology in an amyloid precursor protein (APP)/ presenilin1 (PS1) double transgenic mouse model of Alzheimer’s disease (AD). Non-transgenic and transgenic mice were treated with quetiapine (0, 2.5, or 5 mg/kg/day) in drinking water from the age of 2 months. After continuous treatment with quetiapine for 4 months, mice were tested for memory on a water maze task. After the behavioral test, mice were sacrificed for Western blot and biochemical measurements at the age of 6 months. The chronic administration of quetiapine prevented memory impairment and attenuated brain Aβ plaque formation in the transgenic mice. Furthermore, quetiapine up-regulated cerebral Bcl-2 protein, and attenuated cerebral nitrotytosine, a protein marker of oxidative stress in the transgenic mice. These results suggest that quetiapine is neuroprotective and can treat and alleviate the neuropathology in the AD transgenic mice, and indicate that quetiapine may have therapeutic effects in the treatment of AD.